Semaglutide Side Effects: What to Track

Semaglutide (Ozempic, Wegovy) has a well-characterized side effect profile built from clinical trials involving tens of thousands of participants. The majority of side effects are gastrointestinal, dose-related, and most pronounced during the titration phase. A smaller set of side effects are rare but serious and require immediate medical attention.

Understanding which side effects are expected nuisances versus warning signs is the difference between managing your treatment confidently and either panicking over normal symptoms or ignoring ones that matter.

Common GI Side Effects

Gastrointestinal effects account for the vast majority of reported side effects with semaglutide. These are a direct consequence of how the drug works: GLP-1 receptor activation slows gastric emptying, alters gut motility, and changes appetite signaling in the brain. Your digestive system is adjusting to a fundamentally different operating tempo.

Nausea

Frequency: 20-44% of patients in clinical trials, depending on formulation and dose. The STEP 1 trial (Wegovy 2.4 mg) reported nausea in 44% of participants versus 18% on placebo.

Pattern: Typically worst during the first 1-2 weeks after starting or after each dose escalation. Most patients see significant improvement by weeks 3-4 at a given dose. Nausea that persists beyond a month at the same dose is worth discussing with your prescriber.

What helps: Eat smaller, more frequent meals. Avoid high-fat and greasy foods, which slow gastric emptying further. Stay hydrated. Some prescribers add ondansetron (Zofran) for patients with severe nausea during titration. Eating slowly and stopping before you feel full — even if the portion looks small — can make a meaningful difference.

What to log: Rate your nausea daily on a simple 0-3 scale (none, mild, moderate, severe). Note the time of day it's worst, what you ate beforehand, and whether it improves or worsens over the week. This data lets your prescriber make informed titration decisions.

Diarrhea

Frequency: 15-30% of patients. STEP 1 reported 30% with semaglutide versus 16% with placebo.

Pattern: Often intermittent rather than constant. May be triggered by specific foods, especially those high in fat or sugar. Tends to improve with time at each dose level.

What to log: Frequency per day and consistency. Note any dietary triggers. Persistent diarrhea (more than 3 loose stools daily for more than a week) warrants a provider call, primarily because of dehydration and electrolyte concerns.

Vomiting

Frequency: 13-24% of patients. More common during dose escalation than at steady-state dosing.

When it matters: Occasional vomiting during the first week at a new dose is within the expected range. Vomiting that prevents you from keeping food or fluids down for more than 24 hours is a reason to contact your provider. Persistent vomiting can also signal pancreatitis (more on that below).

What to log: Date, time relative to injection, frequency, and whether you can tolerate fluids afterward.

Constipation

Frequency: 12-24% of patients. Because semaglutide slows gastric emptying and overall gut transit time, reduced bowel frequency is a predictable effect.

What helps: Adequate water intake (most people underestimate this), dietary fiber, and physical activity. If dietary measures aren't sufficient, over-the-counter osmotic laxatives like polyethylene glycol (MiraLAX) are commonly used. Talk to your pharmacist or provider before starting any laxative long-term.

What to log: Bowel frequency (daily or every other day is enough granularity) and whether you're using any interventions.

Abdominal Pain

Frequency: 6-11% of patients. Usually described as cramping or a dull ache in the upper abdomen, often associated with the other GI effects.

When to escalate: Mild, transient cramping that correlates with nausea or dietary changes is typical. Severe abdominal pain — especially pain that radiates to the back, worsens after eating, or is accompanied by persistent vomiting — could indicate pancreatitis and requires immediate medical evaluation.

Injection Site Reactions

Mild reactions at the injection site occur in about 3-5% of semaglutide users. These include:

• Redness or pinkness at the injection point (usually fades within 24-48 hours)
• Small bruise (more common if you hit a capillary — not a sign of technique failure, just anatomy)
• Mild itching at the site
• Small, firm lump that resolves within a few days

These are generally harmless and don't require treatment. If redness spreads, the site becomes warm to the touch, or you see signs of infection (increasing swelling, pus, red streaking), contact your provider.

Reducing injection site reactions: Rotate sites consistently, let alcohol prep dry completely before inserting the needle, don't inject into areas with existing bruises or firm spots, and avoid rubbing the site after injection.

Less Common But Notable Side Effects

Fatigue

Not prominently featured in prescribing information but frequently reported by patients. This may be partly related to reduced caloric intake (your body is adjusting to eating less) rather than a direct drug effect. Ensuring adequate protein intake (at least 0.7g per pound of body weight) and staying hydrated can help. Persistent, debilitating fatigue should be discussed with your provider.

Headache

Reported in 13-14% of patients in STEP trials. Usually mild and responsive to standard OTC analgesics. More common in the first few weeks. If you're also experiencing reduced food intake, headaches may be partially attributable to blood sugar fluctuations or dehydration.

Dizziness

Reported in about 7% of patients. May be related to blood pressure changes (semaglutide modestly lowers blood pressure) or dehydration from GI effects. If you're also on blood pressure medication, your provider may need to adjust those doses as semaglutide takes effect.

Hair Thinning

Reported by approximately 3% of semaglutide patients in STEP 1 versus 1% on placebo. This is most likely telogen effluvium — a well-known response to rapid weight loss and caloric deficit, not a direct pharmacological effect of semaglutide. The hair growth cycle shifts more follicles into the resting/shedding phase during metabolic stress. This is typically temporary, with regrowth beginning once weight stabilizes and nutritional intake is adequate.

Increased Heart Rate

Semaglutide causes a small, sustained increase in resting heart rate — typically 2-4 beats per minute on average. This is a known class effect of GLP-1 receptor agonists. In most patients, this is clinically insignificant. If you have pre-existing cardiac arrhythmias or notice a resting heart rate consistently above 100 bpm, discuss it with your cardiologist or prescriber.

Rare but Serious Risks

These side effects are uncommon but require awareness because they demand immediate action.

Pancreatitis

Risk level: Rare. Incidence in clinical trials was less than 0.5%, but it's serious enough to appear as a warning in prescribing information.

What it looks like: Severe, persistent upper abdominal pain, often radiating to the back. Usually accompanied by nausea and vomiting. Pain may worsen after eating. It's qualitatively different from the mild GI discomfort typical of semaglutide — pancreatitis pain is intense and doesn't resolve on its own.

What to do: Stop semaglutide and seek immediate medical attention. Do not wait to see if it improves. If pancreatitis is confirmed, semaglutide should not be restarted.

Risk factors: History of pancreatitis, gallstones, heavy alcohol use, or very high triglycerides increase risk. If you have any of these, your prescriber should be weighing that in the treatment decision.

Thyroid C-Cell Tumors (Boxed Warning)

Semaglutide carries a boxed warning about thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). This warning is based on animal studies in rodents, where semaglutide caused thyroid C-cell tumors at clinically relevant exposures. Whether this translates to humans is unknown — rodent thyroid C-cells respond to GLP-1 receptor activation differently than human thyroid C-cells.

Contraindication: Semaglutide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Monitoring: Report any lump or swelling in your neck, difficulty swallowing, hoarseness, or shortness of breath to your provider promptly.

Gallbladder Events

Cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation) have been reported at higher rates in semaglutide patients than placebo, likely related to rapid weight loss rather than a direct drug effect. Rapid weight loss from any cause increases gallstone risk.

Symptoms to watch for: Sudden, intense pain in the upper right abdomen, pain after eating fatty foods, nausea, fever. These require medical evaluation.

Acute Kidney Injury

Rare, and primarily reported in patients who became severely dehydrated from GI side effects (persistent vomiting or diarrhea). The kidney injury is secondary to dehydration, not direct drug toxicity. Stay hydrated, especially during dose escalation, and seek medical attention if you can't keep fluids down.

Hypoglycemia

Semaglutide alone rarely causes hypoglycemia because its insulin-stimulating effect is glucose-dependent — it only increases insulin when blood sugar is elevated. However, if you're also taking sulfonylureas or insulin, the combination significantly increases hypoglycemia risk. Your prescriber may reduce your sulfonylurea or insulin dose when starting semaglutide.

What to Track and When

Side effect tracking serves two purposes: it gives your prescriber objective data for dosing decisions, and it gives you a record that reveals patterns you'd otherwise miss.

Daily Log (First 4 Weeks at Each Dose Level)

During dose escalation, log daily:

• Nausea severity (0-3 scale)
• Bowel changes (diarrhea episodes, constipation)
• Appetite level and rough food intake
• Energy level
• Any injection site reaction (day of injection only)

Weekly Log (At Maintenance Dose)

Once stable at your maintenance dose, a weekly check-in is sufficient:

• General GI status
• Weight (same scale, same time of day)
• Any new symptoms
• Energy and activity levels

When to Contact Your Provider

Within 24 hours:

• Severe abdominal pain, especially radiating to the back
• Vomiting that prevents fluid intake for more than a day
• Signs of allergic reaction (hives, facial swelling, difficulty breathing)
• Symptoms suggesting gallbladder disease

At your next appointment (non-urgent but worth reporting):

• Side effects that haven't improved after 3-4 weeks at the same dose
• Noticeable hair thinning
• Persistent fatigue affecting daily function
• Resting heart rate consistently above 100 bpm

Immediately (call 911 or go to ER):

• Anaphylaxis symptoms (throat swelling, severe difficulty breathing)
• Signs of severe dehydration (confusion, very dark urine, inability to stand)

Tracking Side Effects with Done Dose

Done Dose includes a symptom logging feature alongside dose tracking, so your side effect data lives in the same place as your injection history and site rotation log. When you see your prescriber, you can show them a timeline that connects dose changes to symptom patterns — which is substantially more useful than trying to remember whether the nausea was worse at 0.5 mg or 1.0 mg.

The app also lets you set custom reminders to log symptoms at specific times, which is helpful during the first weeks at a new dose when daily tracking matters most.

The Side Effect Trajectory

For most patients, the side effect experience follows a predictable arc: symptoms peak in the first two weeks at each dose level, then gradually improve. By the time you've been at your maintenance dose for 8-12 weeks, most GI effects have settled to a manageable baseline or resolved entirely.

The patients who struggle most are usually those who escalate too quickly (against prescribing guidance), don't adjust their eating patterns, or don't communicate with their prescriber when symptoms are more than mild. The clinical data is clear that most people can tolerate semaglutide when the titration is paced properly and side effects are managed proactively rather than endured silently.